Merative

Merative is the company formed when Francisco Partners acquired IBM Watson Health's data, analytics, and imaging assets in 2022. The core products, Micromedex, MarketScan, Merge, Truven, and Curam, are the same ones IBM had built and acquired over decades. The portfolio has shifted since then: Phytel has been retired and no longer appears among Merative's products, while Zelta, a cloud clinical data management platform for trials, has been added. Otherwise what changed is corporate ownership, renewed investment focus, and a cleaner brand unburdened by the Watson Health hype cycle. Merative continues to serve the same hospital, payer, and life sciences customers.

MarketScan is Merative's flagship real-world data product, a de-identified claims and electronic health record database covering over 300 million US patient lives. Pharma companies use it to build cohorts for post-market safety studies, health economics research, and label expansion. Academic researchers use it for outcomes and disparities studies. Payers benchmark cost and utilization. It is one of the most cited real-world evidence datasets in published medical literature.

Yes, but selectively. Merative now markets Micromedex with AI-powered search, which gets clinicians to the same trusted, curated drug and protocol content faster; note that Merative's own wording is AI-powered search rather than a generative chatbot. Merge imaging applies AI for worklist prioritization and anomaly flagging. MarketScan uses ML to accelerate cohort discovery. Merative is more conservative than health AI startups because its customers are regulated and demand validated, explainable outputs.

Merative does not publish pricing. Costs depend on product line, user count, data volumes, and support tier. Micromedex for a small community hospital can be low five figures per year. MarketScan research licenses for pharma are commonly six figures annually. Merge imaging deployments at large health systems can exceed seven figures. Every contract is custom, multi-year, and negotiated through Merative enterprise sales.

Yes. Merative is HIPAA compliant, HITRUST certified, and serves as a Business Associate for its healthcare customers under standard BAAs. MarketScan data is fully de-identified under HIPAA Safe Harbor and Expert Determination methods. Merative's imaging and EHR-adjacent products include the audit logs, access controls, and data-handling protections required by US and EU healthcare regulation.

Epic and Oracle Cerner are electronic health record systems, the systems of record clinicians use every day. Merative is not an EHR; it is the analytics, reference, and data layer that sits alongside or on top of EHRs. Hospitals typically run Epic or Cerner for clinical workflow and then license Merative products like Micromedex, Merge, or Truven for drug references, imaging, and analytics. The two are complementary, not competitive.

Small clinics, solo physicians, consumer health startups, and anyone looking for modern self-serve SaaS should avoid Merative. Its products assume enterprise buyers, long procurement cycles, and dedicated IT integration teams. If you just need a drug reference app or a simple imaging viewer, lighter-weight alternatives will be faster to deploy and far cheaper.